Merck & Co

News

UK first to authorise Merck/Ridgeback's COVID pill molnupira...

Merck & Co and Ridgeback's oral antiviral molnupiravir has been approved in its first market – the UK – as a treatment for people with mild to moderate COVID-19 who are at increased ris

News

Gilead tags Merck for first-line triple negative breast canc...

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get?

News

Merck takes further steps to expand access to oral COVID pil...

Merck & Co has signed a licensing deal with the UN-backed Medicines Patent Pool (MPP) that could pave the way for generic companies to manufacture its much-anticipated oral antiviral fo

News

EU starts review of Merck's oral COVID drug molnupiravir

The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics' much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults.

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News